Floatz logo

Buprenorphine

Opiate Dependence

Erin WinstanleySmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Opiate Dependence cohort.

Asset / SponsorPhaseRating
Lidocaine
University Medical Centre Ljubljana
Phase 4BB
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
University of California, San Francisco
Phase 4BB
Marcaine
Denver Health and Hospital Authority
Phase 4BB
Gabapentin
Brigham and Women's Hospital
Phase 4BB
Biktarvy
Saskatchewan Health Authority - Regina Area
Phase 4BB

View all 28 →

Same molecule, other indications

Buprenorphine is also rated in:

osteoarthritisDormant
BBB
Indicative · Phase 4
75 / 100
View asset →
chronic pain syndromeActive
BBB
Indicative · Phase 4
73 / 100
View asset →
depressive disorderDormant
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →